The pharmacogenetics of efavirenz metabolism in children: The potential genetic and medical contributions to child development in the context of long-term ARV treatment

Standard

The pharmacogenetics of efavirenz metabolism in children: The potential genetic and medical contributions to child development in the context of long-term ARV treatment. / Tan, Mei; Bowers, Megan; Thuma, Phil; Grigorenko, Elena L. .

In: New Directions for Child and Adolescent Development, Vol. 2020, No. 171, 29.08.2020, p. 107-133.

Research output: Contribution to journal › Review article › peer-review

BibTeX

@article{1ee47c06e8c54ff79a95c39e86f90ce5,

title = "The pharmacogenetics of efavirenz metabolism in children: The potential genetic and medical contributions to child development in the context of long-term ARV treatment",

abstract = "Efavirenz (EFV) is a well‐known, effective anti‐retroviral drug long used in first‐line treatment for children and adults with HIV and HIV/AIDS. Due to its narrow window of effective concentrations, between 1 and 4 μg/mL, and neurological side effects at supratherapeutic levels, several investigations into the pharmacokinetics of the drug and its genetic underpinnings have been carried out, primarily with adult samples. A number of studies, however, have examined the genetic influences on the metabolism of EFV in children. Their primary goal has been to shed light on issues of appropriate pediatric dosing, as well as the manifestation of neurotoxic effects of EFV in some children. Although EFV is currently being phased out of use for the treatment of both adults and children, we share this line of research to highlight an important aspect of medical treatment that is relevant to understanding the development of children diagnosed with HIV.",

author = "Mei Tan and Megan Bowers and Phil Thuma and Grigorenko, {Elena L.}",

note = "Publisher Copyright: {\textcopyright} 2020 Wiley Periodicals, Inc.",

year = "2020",

month = aug,

day = "29",

doi = "doi: 10.1002/cad.20353",

language = "English",

volume = "2020",

pages = "107--133",

journal = "New Directions for Child and Adolescent Development",

issn = "1520-3247",

publisher = "Wiley-Blackwell",

number = "171",

}

RIS

TY - JOUR

T1 - The pharmacogenetics of efavirenz metabolism in children: The potential genetic and medical contributions to child development in the context of long-term ARV treatment

AU - Tan, Mei

AU - Bowers, Megan

AU - Thuma, Phil

AU - Grigorenko, Elena L.

PY - 2020/8/29

Y1 - 2020/8/29

N2 - Efavirenz (EFV) is a well‐known, effective anti‐retroviral drug long used in first‐line treatment for children and adults with HIV and HIV/AIDS. Due to its narrow window of effective concentrations, between 1 and 4 μg/mL, and neurological side effects at supratherapeutic levels, several investigations into the pharmacokinetics of the drug and its genetic underpinnings have been carried out, primarily with adult samples. A number of studies, however, have examined the genetic influences on the metabolism of EFV in children. Their primary goal has been to shed light on issues of appropriate pediatric dosing, as well as the manifestation of neurotoxic effects of EFV in some children. Although EFV is currently being phased out of use for the treatment of both adults and children, we share this line of research to highlight an important aspect of medical treatment that is relevant to understanding the development of children diagnosed with HIV.

AB - Efavirenz (EFV) is a well‐known, effective anti‐retroviral drug long used in first‐line treatment for children and adults with HIV and HIV/AIDS. Due to its narrow window of effective concentrations, between 1 and 4 μg/mL, and neurological side effects at supratherapeutic levels, several investigations into the pharmacokinetics of the drug and its genetic underpinnings have been carried out, primarily with adult samples. A number of studies, however, have examined the genetic influences on the metabolism of EFV in children. Their primary goal has been to shed light on issues of appropriate pediatric dosing, as well as the manifestation of neurotoxic effects of EFV in some children. Although EFV is currently being phased out of use for the treatment of both adults and children, we share this line of research to highlight an important aspect of medical treatment that is relevant to understanding the development of children diagnosed with HIV.

UR - http://www.scopus.com/inward/record.url?scp=85090028346&partnerID=8YFLogxK

UR - https://www.mendeley.com/catalogue/f128bf7e-6edc-340a-9b6b-1c0f6b5f4cf2/

U2 - doi: 10.1002/cad.20353

DO - doi: 10.1002/cad.20353

M3 - Review article

VL - 2020

SP - 107

EP - 133

JO - New Directions for Child and Adolescent Development

JF - New Directions for Child and Adolescent Development

SN - 1520-3247

IS - 171

ER -

ID: 62765441